Creative Biolabs is a contract research organization specialized in offering customized services for the development of antibodies for use in diagnostics, drug discovery, and basic research. Especially, we provide the expertise and personnel to offer high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of high-value diagnostic biomarkers to our clients. Here, we introduce our IVD antibody development services for the lysophosphatidic acid marker.
Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) is one of the simplest natural phospholipids that composed of a single fatty acyl chain, a glycerol backbone, and a free phosphate group. Unlike most other phospholipids, LAP is water soluble and works as a major active constituent of serum.
Lysophosphatidic Acid
LPA is a main membrane-derived multifunctional lipid mediator which plays important roles in stimulating cell (both normal and malignant) proliferation, migration, and survival by acting on its cognate G-protein-coupled receptor (GPCR). The production of LPA predominantly occurs extracellularly by secreted enzymes while it also partially happened intracellularly. Three pathways have been reported to mediate the production of LPA which include the deacylation of phosphatidic acid by phospholipase A2 in inflammatory cells, activated platelets, endothelial cells, and cancer cells, the cleavage of lysophosphatidylcholine by lysophospholipase D (lysoPLD) in blood, and non-enzymatic, mild oxidation of low-density lipoprotein. With regard to the primary molecular mechanism, six different LAP receptors (LPA1R to LPA6R) have been reported and it has been identified that they share a common GPCR structure. LPA1R, LPA2R, and LPA3R are members of the endothelial differentiation gene family encompassing the receptors for sphingosine-1-phosphate. LPA4R and LPA6R belong to the purinergic GPCR family, and LPA5R belongs to the GPR family. And all six receptors can be expressed throughout the body during development and adulthood in unique spatiotemporal patterns.
Lysophosphatidic Acid as a Biomarker for Metabolic Diseases
LPA elicits a wide range of cell responses (contraction, aggregation, calcium mobilization, chemotaxis, neurotransmitter release, cell proliferation, cell transformation), and has been associated with the etiology of a growing number of disorders including cancer, obesity, fibrosis, atherosclerosis and cardiovascular disease, Alzheimer disease, psychiatric disorders such as schizophrenia and bipolar disorders, ischemic cerebrovascular disease, and hydrocephalus. Abnormal LPA production, receptor expression, and signaling may contribute to cancer initiation, progression, and metastasis. Several studies have reported that the regulation of the autotaxin (ATX)/LPA axis in adipose tissue is associated with obesity and the expression of LAP, autotaxin, and acylglycerol kinase is thought to be biomarkers in diabetic retinopathy. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade is regarded as a proposal of a novel potential therapeutic target for the treatment of glioblastoma multiforme.
IVD antibodies have been commonly used in immunodiagnostic kits for disease diagnosis and prognosis. Creative Biolabs has built a versatile IVD platform to provide custom biomarker-specific IVD antibody development services to global clients. Along with over a decade of rich experience in providing excellent custom services for IVD antibody discovery, our services can totally meet your special requirements. If you are interested in our services, please do not hesitate to contact us for more details.
For Research Use Only.
